Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: Implications for antiangiogenic/antithrombotic strategies

British Journal of Dermatology

Volumn 162, Issue 2, 2010, Pages 350-356

  Redondo, P ^a   Aguado, L ^a   Marquina, M ^a   Paramo, J A ^a   Sierra, A ^a   Sanchez Ibarrola A ^a   Martinez Cuesta A ^a   Cabrera, J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Angiogenesis; D dimer; Klippel Trenaunay syndrome; Thrombosis; Vascular malformations

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BIOLOGICAL MARKER; D DIMER; FIBRIN; FIBRINOGEN; GELATINASE A; GELATINASE B; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; CLINICAL ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; ENDOTHELIUM LESION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANGIOGENIC PROTEINS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD FLOW VELOCITY; FEMALE; FIBRINOGEN; HUMANS; KLIPPEL-TRENAUNAY-WEBER SYNDROME; MALE; SYNDROME; VASCULAR MALFORMATIONS; YOUNG ADULT;

EID: 74349107185     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09513.x     Document Type: Article

References (39)

1. Enjolras O, Mulliken JB. Vascular malformations. In : Textbook of Pediatric Dermatology (Harper J, Oranje A, Prose N, eds). Oxford : Blackwell Science Ltd, 2000 975 997.
2. Vikkula M, Boon LM, Carraway KL et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996 87 : 1181 1190.
3. Klippel M, Trénaunay P. Du naevus variquex osteohypertrophique. Arch Gen Med (Paris) 1900 3 : 641 672.
4. Servelle M. Klippel and Trenaunay's syndrome. 768 operated cases. Ann Surg 1985 201 : 365 373.
5. Tian XL, Kadaba R, You SA et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004 427 : 640 645.
6. Barker KT, Foulkes WD, Schwartz CE et al. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet 2006 43 : 613 614.
7. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002 99 : 11205 11210.
8. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997 277 : 55 60.
9. Redondo P, Martínez-Cuesta A, Quetglas EG, Idoate M. Active angiogenesis in an extensive arteriovenous vascular malformation. Arch Dermatol 2007 143 : 1043 1045.
10. Mason KP, Neufeld EJ, Karian VE et al. Coagulation abnormalities in pediatric and adult patients after sclerotherapy or embolization of vascular anomalies. AJR Am J Roentgenol 2001 177 : 1359 1363.
11. Mazoyer E, Enjolras O, Laurian C et al. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol 2002 24 : 243 251.
12. Marler J, Fishman S, Kilroy SM et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 2005 116 : 38 45.
13. Meijer-Jorna LB, van der Loos CM, de Boer OJ et al. Microvascular proliferation in congenital vascular malformations of skin and soft tissue. J Clin Pathol 2007 60 : 798 803.
14. Hashimoto T, Wu Y, Lawton MT et al. Coexpression of angiogenic factors in brain arteriovenous malformations. Neurosurgery 2005 56 : 158 165.
15. Hashimoto T, Lam T, Boudreau NJ et al. Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ Res 2001 89 : 111 113.
16. Geva E, Ginzinger DG, Moore DH 2nd. et al. In utero angiopoietin-2 gene delivery remodels placental blood vessel phenotype: a murine model for studying placental angiogenesis. Mol Hum Reprod 2005 11 : 253 260.
17. Fiedler U, Scharpfenecker M, Koidl S et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004 103 : 4150 4156.
18. Goettsch W, Gryczka C, Korff T et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol 2008 214 : 491 503.
19. Sun JF, Phung T, Shiojima I et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 2005 102 : 128 133.
20. Niu Q, Perruzi C, Voskas D et al. Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 2004 3 : 402 405.
21. DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004 298 : 167 177.
22. Daly C, Wong V, Burova E et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO 1). Genes Dev 2004 18 : 1060 1071.
23. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nature Rev Mol Cell Biol 2009 10 : 165 177.
24. Daly C, Pasnikowski E, Burova E et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 2006 103 : 15491 15496.
25. Belluci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993 70 : 736 742.
26. Wagner DD. Cell biology of von Willebrand factor. Ann Rev Cell Biol 1990 6 : 217 246.
27. Bajou K, Masson V, Gerard RD et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001 152 : 777 784.
28. Devy L, Blacher S, Grignet-Debrus C et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002 16 : 147 154.
29. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006 95 : 49 55.
30. Paramo JA, Beloqui O, Colina I et al. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 2005 3 : 662 664.
31. Redondo P. The hidden face of venous malformations. A multidisciplinary therapeutic approach. Arch Dermatol 2008 144 : 922 926.
32. Hellstrom M, Gerhardt H, Kalen M et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001 153 : 543 553.
33. Lindahl P, Johansson BR, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997 277 : 242 245.
34. Dompmartin A, Acher A, Thibon P et al. Localized intravascular coagulopathy is frequently associated with venous malformations. Arch Dermatol 2008 144 : 873 877.
35. Mazoyer E, Enjolras O, Bisdorff A et al. Coagulation disorders in patients with venous malformation of limbs and trunk. (A study in 118 patients). Arch Dermatol 2008 144 : 861 867.
36. Kisucka J, Butterfield CE, Duda DG et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006 103 : 855 860.
37. Moser M, Patterson C. Thrombin and vascular development. Arterioscler Thromb Vasc Biol 2003 23 : 922 930.
38. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 2004 1654 : 13 22.
39. Elly GL. Heparin therapy for bleeding associated with hemangioma. Surgery 1969 65 : 894 897.